Business Description
![Alimera Sciences Inc Alimera Sciences Inc logo](https://static.gurufocus.com/logos/0C000014M7.png?14)
Alimera Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US0162591038
Description
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.21 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 1.71 | |||||
Debt-to-EBITDA | 34.05 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -1.69 | |||||
Beneish M-Score | -0.71 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -31.7 | |||||
3-Year EPS without NRI Growth Rate | 19.3 | |||||
3-Year FCF Growth Rate | -85.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 18.95 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 90.58 | |||||
9-Day RSI | 87.27 | |||||
14-Day RSI | 82.73 | |||||
6-1 Month Momentum % | -24.8 | |||||
12-1 Month Momentum % | 4.32 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.62 | |||||
Quick Ratio | 2.51 | |||||
Cash Ratio | 0.69 | |||||
Days Inventory | 48.71 | |||||
Days Sales Outstanding | 116.3 | |||||
Days Payable | 254.94 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -109.2 | |||||
Shareholder Yield % | -8.27 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.52 | |||||
Operating Margin % | -1.03 | |||||
Net Margin % | -23.74 | |||||
FCF Margin % | -97.79 | |||||
ROE % | -65.7 | |||||
ROA % | -16.14 | |||||
ROIC % | -0.91 | |||||
ROC (Joel Greenblatt) % | -44.86 | |||||
ROCE % | -7.92 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 157.91 | |||||
PS Ratio | 1.45 | |||||
PB Ratio | 7.11 | |||||
EV-to-EBIT | -37.83 | |||||
EV-to-Forward-EBIT | 45.2 | |||||
EV-to-EBITDA | 168.35 | |||||
EV-to-Revenue | 3.82 | |||||
EV-to-Forward-Revenue | 3.27 | |||||
EV-to-FCF | -3.91 | |||||
Price-to-Median-PS-Value | 1.11 | |||||
Earnings Yield (Greenblatt) % | -2.64 | |||||
FCF Yield % | -30.5 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alimera Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 83.373 | ||
EPS (TTM) (€) | -1.448 | ||
Beta | -0.5 | ||
Volatility % | 90.16 | ||
14-Day RSI | 82.73 | ||
14-Day ATR (€) | 0.25989 | ||
20-Day SMA (€) | 3.47225 | ||
12-1 Month Momentum % | 4.32 | ||
52-Week Range (€) | 2.43 - 5.09 | ||
Shares Outstanding (Mil) | 52.39 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Alimera Sciences Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Alimera Sciences Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Alimera Sciences Inc Frequently Asked Questions
What is Alimera Sciences Inc(FRA:ASZ1)'s stock price today?
The current price of FRA:ASZ1 is €5.05. The 52 week high of FRA:ASZ1 is €5.09 and 52 week low is €2.43.
When is next earnings date of Alimera Sciences Inc(FRA:ASZ1)?
The next earnings date of Alimera Sciences Inc(FRA:ASZ1) is 2024-08-09 Est..
Does Alimera Sciences Inc(FRA:ASZ1) pay dividends? If so, how much?
Alimera Sciences Inc(FRA:ASZ1) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |